Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…Abstract Number: 1663 • 2013 ACR/ARHP Annual Meeting
Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
Background/Purpose: Obesity is not only a risk factor for osteoarthritis but also for rheumatoid arthritis (RA). In obese RA patients, disease incidence is higher and…Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…Abstract Number: 1045 • 2013 ACR/ARHP Annual Meeting
Under Reporting Of Cataracts In Randomised Controlled Trials Investigating The Use Of Systemic Glucocorticoids In Patients With Rheumatoid Arthritis
Background/Purpose: Oral glucocorticoid (GC) therapy is used in more than half of patients with rheumatoid arthritis (RA). Cataracts are a recognised treatment-related side effect of…Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting
Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study
Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting
Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting
Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis
Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting
Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…Abstract Number: 50 • 2012 ACR/ARHP Annual Meeting
Human Chondrocyte Dedifferentiation Is Accompagnied by CD105 Endoglin Expression, ALK-1/Smad1/5 Phosphorylation and Leptin Production – Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor
Background/Purpose: Leptin, mainly produced by the adipose tissue including fat neighboring the joint, is considered as pro-inflammatory in osteoarthritis (OA). Normal cartilage does not…
ACR Meeting Abstracts